NanoViricides Inc. (NNVC)

[KMBJN]

He's always emphasizing the fact that there are multi-billion dollar markets for effective treatments for these viruses, intimating that NNVC will get a slice of the pie. It is totally misleading since NNVC has not nor will never (ever?) produce a viable treatment.

For coronavirus, Diwan will apparently be making a drug first and testing on less pathogenic strains that still use the ACE2 receptor. If successful, then he will try to get money (and a license for NNVC).

Hard to predict how successful his drug (coronaviricide with ACE2 mimic ligand) will be, and if governments or others would be willing to finance it going forward.

It's also hard to predict how successful the nanoviricides will be in humans. (Or if NNVC will ever get its act together to get into human testing). Judging by preclinical models in cells, skin-organ culture, and animals, the drugs have a pretty good chance to be effective in humans.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153847095

From the latest 10-Q

The Company determined, based on molecular modeling screening that it had in its chemicals library ligands that could bind to SARS-CoV S1 spike protein at the same position where the S1 binds to the human receptor ACE2. It is a reasonable expectation that these relatively broad-spectrum ligands would also be able to bind the S1 spike protein of the NCP coronavirus in the same fashion. The Company intends to generate nanoviricides based on these ligands and test them in our own BSL2 virology lab facility against known available human pathogen coronaviruses, including those that use ACE2 as the cellular receptor. The Company has the capacity to produce several thousand doses of the potential drug at its cGMP-capable multi-purpose manufacturing facility in Shelton, CT. If this screening produces positive results, then the Company anticipates obtaining assistance from US government and international agencies for further testing and potential exploratory clinical use to combat the epidemic.